Perrigo Company plc announced it has received final FDA approval for the generic version of Valeant Pharmaceutical International, Inc.’s BenzaClin® Pump Topical Gel. Shipments to customers have already commenced.

BenzaClin^® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending February 2016 were $79 million. 

Perrigo’s Chief Executive Officer John T. Hendrickson stated, “This Rx product approval and launch demonstrates the team’s ability to leverage Perrigo’s manufacturing expertise in order to provide our customers with the latest technologies.  Providing our customers with convenient, cost effective technologies like the BenzaClin^® Pump furthers Perrigo’s commitment of delivering Quality Affordable Healthcare Products^® around the world.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!